Effect of Arsenic Exposure on AS3MT Protein Levels in Serum of Type 2 Diabetic Patients Compared to Non-diabetics

This research explores the impact of arsenic exposure on serum protein profiles in type 2 diabetes patients, with an emphasis on the AS3MT protein as a biomarker. Utilizing Bradford protein assay, SDS-PAGE, HPLC, and mass spectrometry, we quantified and analyzed variations in serum protein levels, focusing on differences between control groups (82.94 +/- 8.03 mu g/mL) and diabetic patients (96.95 +/- 5.02 mu g/mL) of high arsenic exposed in areas Kasur and Lahore, Punjab, Pakistan. The study revealed a significant increase in total serum proteins and specifically identified elevated levels of AS3MT in the diabetic group compared to controls. By using 15% gel, proteins were separated, and bands were visible at 42KD. Further investigations using HPLC provided a detailed chromatographic profile of AS3MT, isolating this protein effectively and displaying its heightened abundance through a marked peak within the sample chromatograms. Additionally, intact mass and tryptic digestion profiles analyzed by mass spectrometry (molecular weight of 41,747.79 D) further corroborated the identity and modification of AS3MT in the context of arsenic exposure. ELISA was used for the quantification of AS3MT protein concentration, and a 260% increase was confirmed in the diabetic group exposed to arsenic. These findings suggested that arsenic exposure significantly alters AS3MT protein and serum protein levels in diabetic patients, supporting the hypothesis that AS3MT can serve as a biomarker for arsenic-induced diabetic conditions.